AR069806A1 - Uso de un componente neurotoxico del complejo de toxina botulinica creada por la bacteria clostridium botulinum para reducir o evitar efectos colaterales - Google Patents

Uso de un componente neurotoxico del complejo de toxina botulinica creada por la bacteria clostridium botulinum para reducir o evitar efectos colaterales

Info

Publication number
AR069806A1
AR069806A1 ARP080105529A ARP080105529A AR069806A1 AR 069806 A1 AR069806 A1 AR 069806A1 AR P080105529 A ARP080105529 A AR P080105529A AR P080105529 A ARP080105529 A AR P080105529A AR 069806 A1 AR069806 A1 AR 069806A1
Authority
AR
Argentina
Prior art keywords
toxin complex
clostridium botulinum
neurotoxic component
bostery
reduce
Prior art date
Application number
ARP080105529A
Other languages
English (en)
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of AR069806A1 publication Critical patent/AR069806A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

El uso de un componente neurotoxico de un complejo de toxina botulínica creada por la bacteria Clostridium botulinum para el tratamiento cosmético facial de un ser humano o animal susceptible de sufrir los efectos de cara de muneca o cara congelada. Componente neurotoxico de un complejo de toxina botulínica creada por la bacteria Clostridium botulinum para el tratamiento de una enfermedad o trastorno causado por o asociado con la inervacion colinérgica hiperactiva o glándulas exocrinas en un humano o animal susceptible de sufrir efectos colaterales asociados con el tratamiento de dicha enfermedad o trastorno con el complejo de toxina botulínica creada por la bacteria Clostridium botulinum.
ARP080105529A 2007-12-21 2008-12-18 Uso de un componente neurotoxico del complejo de toxina botulinica creada por la bacteria clostridium botulinum para reducir o evitar efectos colaterales AR069806A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US901007P 2007-12-21 2007-12-21
EP07024961A EP2072039A1 (en) 2007-12-21 2007-12-21 Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects

Publications (1)

Publication Number Publication Date
AR069806A1 true AR069806A1 (es) 2010-02-17

Family

ID=39401018

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105529A AR069806A1 (es) 2007-12-21 2008-12-18 Uso de un componente neurotoxico del complejo de toxina botulinica creada por la bacteria clostridium botulinum para reducir o evitar efectos colaterales

Country Status (13)

Country Link
US (1) US20100331259A1 (es)
EP (2) EP2072039A1 (es)
JP (1) JP2011506511A (es)
KR (1) KR20100107475A (es)
CN (1) CN101917960A (es)
AR (1) AR069806A1 (es)
AU (1) AU2008340713A1 (es)
CA (1) CA2709644A1 (es)
IL (1) IL206423A0 (es)
MX (1) MX2010006731A (es)
RU (1) RU2010130542A (es)
WO (1) WO2009080272A1 (es)
ZA (1) ZA201004393B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792344B2 (en) * 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
US9161970B2 (en) 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11602303B2 (en) * 2017-02-10 2023-03-14 Mauricio De Maio Domingos Methods and systems for preventing, correcting, transforming, and modifying facial, aesthetics, and consulting patients regarding the same
US11738071B2 (en) 2021-07-12 2023-08-29 Penland Foundation Treatment of acute and chronic kidney disease
US10973873B1 (en) 2019-10-18 2021-04-13 Penland Foundation Treatment of asthma using botulinum toxin
US10960060B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of cardiac arrhythmia using botulinum toxin
US10987411B1 (en) 2019-10-18 2021-04-27 Penland Foundation Treatment of chronic obstructive pulmonary disease using botulinum toxin
US11090371B1 (en) * 2019-10-18 2021-08-17 Penland Foundation Treatment of cirrhosis using botulinum toxin
KR102520625B1 (ko) 2019-10-18 2023-04-12 펜랜드 파운데이션 치료에 사용하기 위한 보톨리늄 독소
US11241479B2 (en) 2019-10-18 2022-02-08 Penland Foundation Treatment methods using botulinum toxins
US10960061B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
KR102397708B1 (ko) * 2020-04-29 2022-05-16 한국화학연구원 탄닌산을 포함하는 보툴리눔 독소 약제학적 조성물
KR20230007129A (ko) 2021-07-05 2023-01-12 주식회사 파마리서치바이오 클로스트리디움 보툴리눔 독소 복합체 단백질의 정제방법
KR20230009178A (ko) 2021-07-08 2023-01-17 주식회사 파마리서치바이오 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법
WO2023287728A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin
KR102551301B1 (ko) 2022-10-28 2023-07-03 주식회사 파마리서치바이오 보툴리눔 독소를 포함하는 안정한 액상 제제

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1477183B1 (en) * 1993-12-28 2005-11-02 Allergan, Inc. Neurotoxic component of Botulinum toxin for modulating cholinergic controlled secretions
US8187612B2 (en) * 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
DE60125986T3 (de) 2000-02-08 2011-07-28 Allergan, Inc., 92612, Calif. Pharmazeutische Zusammensetzungen mit Botulinum Toxin
US6503653B2 (en) * 2001-02-23 2003-01-07 General Motors Corporation Stamped bipolar plate for PEM fuel cell stack
JP3830766B2 (ja) * 2001-03-09 2006-10-11 本田技研工業株式会社 燃料電池および燃料電池スタック
JPWO2003082315A1 (ja) * 2002-03-29 2005-07-28 財団法人化学及血清療法研究所 筋緊張亢進疾患治療剤
US20040115222A1 (en) * 2002-09-06 2004-06-17 Michael Kane Method for reduction of wrinkles
JP2005089336A (ja) * 2003-09-12 2005-04-07 Tokyo Univ Of Agriculture Ｄ型ボツリヌス神経毒素の精製法
EP2266600B1 (en) * 2004-07-26 2014-09-10 Merz Pharma GmbH & Co. KGaA Therapeutic composition with a botulinum neurotoxin
GB2426702A (en) * 2004-10-28 2006-12-06 Ipsen Ltd Pharmaceutical composition comprising botulinum neurotoxin
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica

Also Published As

Publication number Publication date
CA2709644A1 (en) 2009-07-02
AU2008340713A1 (en) 2009-07-02
US20100331259A1 (en) 2010-12-30
ZA201004393B (en) 2011-08-31
EP2231107A1 (en) 2010-09-29
KR20100107475A (ko) 2010-10-05
CN101917960A (zh) 2010-12-15
MX2010006731A (es) 2010-08-16
EP2072039A1 (en) 2009-06-24
RU2010130542A (ru) 2012-01-27
JP2011506511A (ja) 2011-03-03
WO2009080272A1 (en) 2009-07-02
IL206423A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
AR069806A1 (es) Uso de un componente neurotoxico del complejo de toxina botulinica creada por la bacteria clostridium botulinum para reducir o evitar efectos colaterales
BR112016027773A2 (pt) peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica
CO6640331A2 (es) Tratamiento anti-envejecimiento de la piel
BR112015013123A2 (pt) inibidores de beta-lactamase
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
CA2902938C (en) Peptides for skin rejuvenation and methods of using the same
BR112014006455A2 (pt) alquilamidotiazóis, preparações cosméticas ou dermatológicas com um teor de um ou vários alquilamidotiazóis e uso de um ou vários alquilamidotiazóis
BR112015019064A2 (pt) métodos de tratamento de melanoma
BR112014009418A2 (pt) macrociclos peptidomiméticos
AR088165A1 (es) Proteinas de funcion dual para tratar trastornos metabolicos
CY1114792T1 (el) Κλωστριδιακες τοξινες για χρηση στην θεραπεια προωρης εκσπερματισης
AR028939A1 (es) Metodo para tratar un desorden pancreatico con una neurotoxina
CR20110658A (es) Antagonistas de la trayectoria hedgehog de ftalazina desustituida
CR9351A (es) Composiciones y metodos para aplicaicon topica y suministro transdermico de toxina botulinica
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
BR112013018919A2 (pt) composições de nanopartículas vazias e seu uso para tratamento de problemas dermatológicos
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2022010186A (es) Neurotoxinas botulinas para uso en terapia.
BR112014011481A2 (pt) hidrolisado de colágeno e seu uso
CL2011002650A1 (es) Composicion que comprende n-(4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il)-2-metilpiridin-5-carboxamida y l-dopa; uso del compuesto para el tratamiento de un trastorno del movimiento secundario de la terapia con l-dopa; uso del compuesto y l-dopa y/o para el tratamiento y/o profilaxis de la enfermedad de parkinson.
CL2019003484A1 (es) Neurotoxina botulínica para el tratamiento de trastornos asociados a hiperactividad de melanocitos y/o exceso de melanina.
CL2019001014A1 (es) Métodos de tratamiento de afecciones relacionadas con la inflamación utilizando moduladores metabólicos y anti inflamatorios pluripotentes.
UY34700A (es) Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné
BR112018012749A2 (pt) composições para higiene pessoal
WO2015081306A3 (en) Peptide tyrosinase activators

Legal Events

Date Code Title Description
FA Abandonment or withdrawal